Dr. David H. Donabedian is a Venture Partner at Longwood Fund, Startup CEO of Longwood-founded ImmuneID, and was the founding CEO of Longwood-founded Axial Therapeutics, a biotechnology company focused on the gut-brain axis. He led the organization from inception through Phase II development. Dr. Donabedian has over 20 years of professional experience and expertise leading business development, venture teams and demonstrated track record of company creation.
Prior to joining Longwood, Dr. Donabedian held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GlaxoSmithKline (NYSE: GSK). At AbbVie he served as Vice President and Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President of Global New Deal Strategy and Development at GlaxoSmithKline and Senior Manager at Accenture's Strategic Services Consulting Group.
Dr. Donabedian holds a B.A. in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He serves on the Board of Anuncia Inc. and Alcyone Therapeutics, Inc., a privately held precision CNS gene therapy company he co-founded.